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Abstract
Hepatocellular carcinoma (HCC) is an aggressive tumor 
that often occurs in the setting of chronic liver disease. 
Many patients do not initially manifest any symptoms of 
HCC and present late when cure with surgical resection 
or transplantation is no longer possible. For this reason, 
patients at high risk for developing HCC are subjected 
to frequent screening processes. The surgical manage-
ment of HCC is complex and requires an inter-disci-
plinary approach. Hepatic resection is the treatment of 
choice for HCC in patients without cirrhosis and is indi-
cated in some patients with early cirrhosis (Child-Pugh 
A). Liver transplantation has emerged in the past de-
cade as the standard of care for patients with cirrhosis 
and HCC meeting Milan criteria and in select patients 
with HCC beyond Milan criteria. Loco-regional therapy 
with transarterial chemoembolization, transarterial em-
bolization, radiofrequency ablation and other similar lo-
cal treatments can be used as neo-adjuvant therapy to 
downstage HCC to within Milan criteria or as a bridge 
to transplantation in patients on transplant wait list. 
© 2014 Baishideng Publishing Group Inc. All rights reserved.
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Core tip: This is a review article on the current strate-
gies for the management of hepatocellular carcinoma 
in North America. This article covers the evolution of 
techniques and provides comparison between different 
modalities discussed.
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INTRODUCTION
Hepatocellular carcinoma (HCC) is an aggressive tumor 
that often occurs in the setting of  chronic liver disease 
and cirrhosis. It is the fifth most frequently diagnosed 
cancer worldwide and the third leading cause of  cancer 
death[1]. Traditionally the rates of  HCC in North America 
have been low compared to Asian and sub-Saharan Af-
rican countries (15 per 100000 in Asia and Africa com-
pared to less than 3 per 100000 in North America)[1,2]. 
However, the last two decades have seen a significant 
increase in the incidence of  HCC in the United States 
where the risk of  HCC is linked significantly to chronic 
viral hepatitis (hepatitis C virus and hepatitis B virus), 
alcohol consumption and nonalcoholic fatty liver dis-
ease[3-7]. The presence of  these risk factors predisposes 
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patients to the development of  cirrhosis and HCC by the 
common pathway of  inducing chronic inflammation of  
the liver, which acts as the backdrop for genetic muta-
tions to amass and drive cells towards malignancy[8]. The 
American Association for the Study of  Liver Diseases 
(AASLD), Asian Pacific Association for the Study of  the 
Liver and the European Association for the Study of  the 
Liver, all have well defined guidelines for diagnosis and 
management of  HCC which are fairly similar to each 
other other than some minor differences based on dis-
ease etiology and epidemiology[9-11].
DIAGNOSIS
Patients who develop HCC often have no symptoms 
other than those related to chronic liver disease. Therefore 
it is not unusual for HCC to be diagnosed in advanced 
stages (Table 1) when cure with surgical resection or trans-
plantation is no longer possible. For this reason, patients 
at high risk for developing HCC are subjected to regular 
screening with ultrasound and tumor markers in accor-
dance with the updated guidelines of  AASLD[11]. Patients 
with high index of  suspicion for HCC on screening then 
undergo additional non-invasive testing with either con-
trast enhanced computed tomography (CT) or gadolinium 
enhanced magnetic resonance imaging (Figure 1). These 
imaging modalities can reliably establish the diagnosis of  
HCC in most patients without the need for biopsy and 
also provide information on the size and number of  le-
sions, relationship with vascular structures and evidence 
of  extra-hepatic spread. Additionally, chest CTs and bone 
scans are routinely used to assess for metastatic disease. 
Traditionally Positron emission tomography scan has had 
a limited role in HCC staging as HCC has shown variable 
degrees of  fluorodeoxyglucose (FDG) uptake, which lim-
its sensitivity[12]. However recent application of  PET using 
11C-Acetate and 18F-FDG has shown it to be an effective 
HCC staging modality especially in patients with high al-
pha fetoprotein levels, primary lesions with high SUV max 
values and for lesions beyond Milan criteria[13,14].
Cirrhosis of  the liver underlies HCC in almost 90% 
of  cases and the extent of  underlying cirrhosis plays a 
vital role in determining treatment options and overall 
outcomes[7]. Traditionally, surgical resection has been the 
only option for cure but more often than not, the extent 
of  HCC or the degree of  underlying parenchymal disease 
precludes surgical resection. In the last two decades, liver 
transplantation has emerged as an effective and viable 
option for treatment of  HCC in select patients who oth-
erwise would not have been candidates for surgical resec-
tion[7]. Other therapies such as radiofrequency ablation 
(RFA), microwave ablation, transarterial embolization 
(TAE) and transarterial chemoembolization (TACE) can 
be used alone or in combination with surgical resection 
or transplantation to effectively treat selected patients 
with HCC. Tables 2 and 3 provide a brief  summary of  
the indications, advantages and disadvantages of  the 
commonly used treatment options for management of  
HCC in North America today.
HEPATIC RESECTION
Introduction
Hepatic resection has been the standard treatment for 
HCC in selected patients with limited disease and early 
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Table 1  American liver tumor study group modified tumor-





T0, N0, M0 No tumor found
T1 1 nodule < 2.0 cm Stage Ⅰ T1 lesion
T2 1 nodule 2-5 cm, 2 or 3 nodules 
each less than 3 cm
Stage Ⅱ T2 lesion
T3 1 nodule > 5 cm, 2 or 3 
nodules, at least 1 > 3 cm
Stage Ⅲ T3 lesion
T4a ≥ 4 nodules, any size Stage Ⅳa1 T4a
T4b T2, T3 or T4a plus gross 
intrahepatic, portal or hepatic 
vein involvement as indicated 
by CT, MRI or US
Stage Ⅳa2 T4b
N1 Regional (porta hepatis) node 
involvement
Stage Ⅳb Any N1 or 
M1
M1 Metastatic disease including 
extrahepatic portal or hepatic 
vein involvement
HCC: Hepatocellular carcinoma; CT: Computed tomography; MRI: 
Magnetic resonance imaging; US: Ultrasound; TNM: Tumor node 
metastasis.
Figure 1  Magnetic resonance imaging of hepatocellular carcinoma in 






cirrhosis (Child-Pugh A)[15,16]. With advances in surgical 
technique and better understanding of  disease pathophys-
iology, resection for HCC can now safely be performed 
in most major centers with a peri-operative mortality rate 
of  less than 5%[15-17]. Moreover, five-year survival rates 
of  over 50% have been reported in carefully selected 
patients with small, solitary tumors and well-preserved 
hepatic function, which supports the therapeutic role of  
resection in the treatment algorithm[17-19]. 
Advantages and disadvantages
In theory, hepatic resection for HCC has several advan-
tages when compared to other therapeutic modalities 
such as liver transplantation and thermal ablation. It is 
more readily applicable, does not have an associated wait-
ing time, and is not restricted by tumor size or proximity 
to hepatic veins and portal pedicles[15-17,20]. The effective-
ness of  the surgery can be gauged early by tumor free 
margins on pathologic analysis and the ability to maintain 
an adequately functioning liver remnant. However, not 
every patient with localized HCC is a candidate for resec-
tion. Moreover resection does not address the remnant 
liver, which remains at risk for developing cancer[15,17,21]. 
Prognostic factors
Currently, surgery is preferred in patients with HCC 
without any underlying liver disease and in select patients 
with early cirrhosis (Child-Pugh A)[16,17]. The extent of  
underlying liver dysfunction has repeatedly been shown 
to be an important determinant of  overall outcome with 
peri-operative morbidity and mortality being directly pro-
portional to the degree of  cirrhosis[18,19]. Parenchymal dis-
ease dictates the amount of  resection that can be safely 
done without risking post-operative hepatic failure due to 
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Table 2  Current indications of commonly used treatment options for hepatocellular carcinoma
Current indications
Hepatic resection Treatment of choice in patients with resectable disease and absence of cirrhosis
Indicated in selected patients with limited disease and early cirrhosis (Child-Pugh A)
Limited role as a bridge to OLT
OLT Standard therapy for patients with HCC and Cirrhosis within Milan criteria
OLT may be indicated in select patients with tumors outside Milan criteria but within UCSF criteria
Indicated in select patients with stage III and IV HCC downstaged to within Milan criteria with use of neo-adjuvant therapy
Non resectional 
ablative therapies (RFA, 
microwave, TACE, TAE, 
HIFU etc.)
Indicated as primary therapy only in patients with HCC who are not candidates for curative resection or OLT
Increasingly used alone or in combination as bridging therapy in patients awaiting OLT or to downstage stage advanced 
stage disease to within Milan criteria
Established role in palliative treatment of HCC (not discussed in this paper)
HCC: Hepatocellular carcinoma; OLT: Orthotopic liver transplant; UCSF: University of California San Francisco.
Table 3  Overview of the common modalities used in the treatment of hepatocellular carcinoma
Treatment modality Advantages Disadvantages
Hepatic resection Readily accessible Not indicated for patients with advanced cirrhosis
No waiting period High recurrence rates (> 50% at 5 yr)
5 yr survival of > 50% in carefully selected patients Risk of post operative haptic failure
Peri-operative mortality < 5% Does not address risk of cancer in residual liver
Not limited by tumor size
OLT Low rate of recurrence in carefully selected patients Restricted by size and number of lesions
Post transplant survival rates similar to patients with OLT 
for all other causes
Risk of dropout while on wait list (38% drop out rate after 12 
mo)
TACE/TAE Indicated for treatment in patients not candidates for 
resection or OLT
Low curative potential when used alone with high recurrence 
rates
Effective role as bridge for transplantation Efficacy decreased for large sized tumors
Established role in downstaging HCC to make patients OLT 
eligible
Does not address risk of cancer in residual liver
Evidence of survival benefit after OLT when used as 
neo-adjuvant therapy in select patients
Relatively low morbidity
RFA Highly effective for HCC ≤ 3 cm Decreased effectiveness in HCC ≥ 4 cm with high recurrence 
rates
Effective bridge for OLT by decreasing drop out rate on wait 
list
May be limited by proximity of HCC to vascular pedicels
Established role in downstaging HCC to make patients OLT 
eligible
Does not address risk of cancer in residual liver
Relatively low morbidity and mortality
HCC: Hepatocellular carcinoma; OLT: Orthotopic liver transplantation; TACE: Transarterial chemoembolization; TAE: Transarterial embolization; RFA: 
Radiofrequency ablation.
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for hepatocellular carcinoma in 351 patients. Eighty five 
percent of  the patients had underlying liver disease and 
11% had major hepatectomy. They reported 30-d post-
operative mortality of  2%. Ninety two percent had R0 
resection and reported overall 1, 3 and 5-year survivals of  
90.3%, 70.1% and 65.9% respectively. These results com-
pare favorably with the reported outcomes after open 
resection[29].
HCC in early cirrhosis: Resection vs OLT
The use of  resection for patients with early cirrhosis 
(Child-Pugh A) and HCC that falls within the Milan crite-
ria is a controversial decision at most US centers as these 
patients may instead be candidates for transplantation. 
Studies comparing the two modalities show comparable 
overall adjusted survival. The higher recurrence rate after 
resection is balanced by the risk of  dropout due to disease 
progression in patients awaiting OLT[21,31,32]. At most cen-
ters this decision is made on a case-to-case basis after dis-
cussion in multi-disciplinary meetings and tumor boards.
Hepatic resection as a bridge to orthotopic liver 
transplantation
Several groups have studied surgical resection as a bridge 
to transplantation (this will be discussed more in the sec-
tion on transplantation). One concerning trend noted 
in many of  these studies is the high number of  patients 
(> 30%) with recurrent HCC after liver resection that 
is beyond the Milan criteria, making them ineligible for 
transplantation at most centers[33-35]. However, survival 
after salvage liver transplantation for patients with recur-
rences within Milan Criteria has shown to be comparable 
to survival after primary orthotopic liver transplantation 
(OLT) in a recent meta-analysis of  1508 patients, making 
it a reasonable option in carefully selected patients[36]. 
LIVER TRANSPLANT
Introduction
Liver transplantation is now considered standard therapy 
for selected patients with early stage HCC and liver cir-
rhosis[12,21]. Initial experience with liver transplantation for 
HCC resulted in dismal outcomes. High recurrence rates 
(65%-75%) and poor survival seen in these early reports 
considerably diminished the interest in liver replacement 
for hepatic malignancy and a moratorium was placed on 
liver transplantation for HCC outside of  clinical trials in 
1989[37-39].
Milan criteria for transplantation for HCC
Interest in liver transplantation for HCC was renewed in 
1996, when Mazzaferro and his group showed survival 
after liver transplantation in patients with cirrhosis and 
early-stage HCC to be comparable to results after liver 
transplantation in patients with benign disease[40]. This 
prospective cohort study included 48 cirrhotic patients 
who underwent transplantation for HCC with single tu-
mors less than or equal to 5 cm or up to 3 tumors, each 3 
a small liver remnant[18,19,21]. Cirrhosis also increases the 
risk of  peri-operative bleeding and the need for blood 
transfusions, factors shown to be independently associ-
ated with increased morbidity and mortality[15,20].
The size of  HCC and total number of  lesions are 
important determinants of  outcome after hepatec-
tomy[15,18,22]. Zhou et al[16], in their review of  1000 patients 
undergoing hepatectomy for HCC observed that patients 
with tumors greater than 5 cm had a significantly lower 
survival when compared to those with smaller lesions 
(37% vs 63%). Similarly, Fong et al[17] reported five-year 
survival of  57% for patients with resected lesions less 
than 5 cm and only 32% for patients with tumors greater 
than 10 cm. However, a more recent study from the same 
group showed that in carefully selected patients with large 
tumors (> 10 cm), resection can achieve similar overall 
survival and recurrence-free survival as patients with 
smaller tumors[23]. Multi-focal or multi-nodular HCC is a 
poor prognostic sign and hepatectomy in these patients is 
associated with high recurrence rates (> 90%) and poor 
survival (< 30%)[18,19,24].
Vascular invasion has repeatedly been shown to be 
one of  the strongest negative prognosticators in patients 
undergoing hepatectomy for HCC[20,25,26]. Lang demon-
strated 1, 3 and 5-year survival rates of  57%, 16% and 6% 
respectively in patients undergoing resection for HCC 
with vascular invasion compared to 93%, 75% and 53% 
in patients without vascular invasion[20]. Five-year survival 
after hepatectomy in patients with vascular invasion may 
be increased to over 20% in the absence of  underlying 
liver fibrosis[26].
There have been many studies looking at the impact 
of  resection margin on recurrence and survival after 
HCC resection. Though there is universal consensus that 
an R0 resection is better than a resection with positive 
margins, there are no clear-cut guidelines on the mini-
mum negative margin required[20]. A recent randomized 
trial compared resection outcomes for solitary HCC 
by randomizing 169 patients to undergo hepatic resec-
tion with either narrow (1 cm) or wide (2 cm) resection 
margins. Both groups were matched for tumor size. The 
authors reported significantly improved survival and re-
duced tumor recurrence in the wide margin group[27]. A 
more recent meta-analysis did not show a significant dif-
ference in outcomes after hepatectomy for HCC between 
resection margins less than 1 cm and margins equal to or 
greater than 1 cm[28].
Some additional factors associated with reduced sur-
vival after hepatectomy for HCC include presence of  
satellite lesions or intra-hepatic metastases, poor tumor 
differentiation, elevated alkaline phosphatase levels and 
high serum alpha-fetoprotein levels[18,19,22,25].
There have been several reports recently on laparo-
scopic resections for HCC. Most of  these reflect highly 
selected patients with isolated and easily accessible 
disease, which makes direct comparison with open re-
section difficult[29,30]. A recent multicenter cohort study 
from France reviewed results of  laparoscopic resection 
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cm or less in diameter. The actuarial 4-year survival was 
75%, which was not different from expected survival of  
patients with non-malignant indications[40]. This study 
formed the basis for the Milan criteria. These results were 
validated by several studies and interest in transplantation 
as a therapeutic option for patients with early stage HCC 
was renewed.
Model for end stage liver disease allocation and 
exception points for HCC
Currently in the US, livers are allocated for transplanta-
tion using the model for end stage liver disease (MELD) 
score, which predicts the three-month mortality of  pa-
tients awaiting liver transplantation. Realizing that the 
MELD system would be of  little benefit to patients with 
compensated cirrhosis and early stage HCC, UNOS in 
2002 adopted the Milan criteria for allocating exception 
points to patients with HCC listed for liver transplanta-
tion. At the present time, patients with stage 2 HCC (Mi-
lan criteria - 1 nodule up to 5 cm or 3 nodules with the 
largest one 3 cm or less) can receive 22 MELD exception 
points which decreases the wait time for receiving a liver 
to between 6 mo and 12 mo at most transplant centers in 
North America[37,41]. Currently patients with cirrhosis and 
HCC beyond Milan criteria do not qualify for MELD 
exception points despite otherwise meeting criteria for 
OLT. These patients can be listed for OLT based on their 
original MELD score, however the likelihood of  timely 
OLT before HCC progression is small without allocation 
of  priority points. Transplant centers can selectively peti-
tion regional review boards for MELD exception points 
in HCC patients exceeding Milan Criteria or in those who 
have been effectively down-staged and are considered on 
a case to case basis[21,37].
Results for survival and disease free interval after liver 
transplantation for patients have significantly improved 
after implementation of  the Milan criteria. In a review 
of  their 20-year experience with liver transplantation 
for HCC, Onaca et al[42] reported an increase in five year 
patient survival from 28.6% in 1987-1992 and 42.3% in 
1992-1997 to 76% after 1997, when Milan criteria was 
implemented. Similar observations were made in several 
other studies and as a result, the number of  liver trans-
plants performed annually in the US for HCC increased 
almost three fold between 2002 and 2006[21]. In most re-
cent series, the overall five and ten year survival following 
transplantation for HCC is comparable to the five and 
ten-year survival rates for all causes[12,21,37].
Extended criteria for transplantation for HCC
In recent years there has been a push by many transplant 
centers for expanding the Milan criteria. It is felt that the 
Milan criteria is too restrictive and limits the use of  trans-
plantation to patients with very early stage HCC. Several 
groups have challenged these restrictions by either ex-
panding the inclusion criteria or by using liver directed 
therapy to downstage patients with advanced disease to 
“within Milan criteria”. The most notable contribution in 
this regard came from the University of  California San 
Francisco (UCSF) group who proposed expanding the 
Milan criteria to include single lesion ≤ 6.5 cm or up to 3 
lesions, the largest ≤ 4.5 cm and total tumor diameter ≤ 
8 cm without gross vascular invasion[43]. The group based 
their recommendations on the observation that the ex-
plant pathology often showed under-staging of  HCC by 
preoperative cross sectional imaging and that this did not 
appear to impact the overall outcome. The initial paper 
reviewed 168 HCC patients that under underwent OLT 
and reported a 5-year recurrence free survival of  90% 
for patients with tumors within Milan vs 94% for patients 
with tumors that exceeded Milan but were within the 
UCSF criteria[43]. A follow-up study from the same group 
again evaluated the expanded criteria in 467 patients and 
showed that patients meeting Milan criteria had similar 
5-year post transplant survival to patients meeting UCSF 
criteria by preoperative imaging (79% vs 64%) and ex-
plant pathology (86% vs 71%)[44]. Since then several other 
centers have reported similar results in patients exceeding 
Milan criteria[45-49].
Beyond UCSF?
There is little enthusiasm for extending liver transplanta-
tion beyond the UCSF criteria as survival has shown to 
be significantly reduced once the size exceeds UCSF cri-
teria[44,45]. This has led to a renewed interest in using neo-
adjuvant techniques for downsizing prohibitively large 
HCC’s in patients who may otherwise be amenable for 
transplantation. 
Down-staging advanced stage HCC
Selected patients with advanced stage HCC (stage Ⅲ/Ⅳ) 
who are not candidates for transplantation can be down-
staged with the use of  neo-adjuvant loco-regional therapy 
to “within Milan criteria” so that they can become trans-
plant eligible. This practice has been adopted by an in-
creasing number of  transplant centers in North America 
with promising results. A recent report from Washington 
University in St Louis demonstrated the feasibility of  this 
approach by successfully down-staging 18 of  76 patients 
(23.7%) with stage Ⅲ/Ⅳ disease to ‘‘within the Milan 
criteria’’ using TACE. Seventeen of  these patients went 
on to receive OLT at a median of  58 ± 3.5 mo after first 
TACE with an actuarial overall 5-year survival rate of  
93.8%. This compared favorably to a 5-year survival rete 
of  66% in patients with stage Ⅱ disease that were chemo-
embolized and transplanted[50]. Similar results were report-
ed by the UCSF group who utilized TACE for tumors ex-
ceeding Milan but within UCSF criteria. Forty-three of  61 
patients (70.5%) were successfully down-staged, of  which 
35 went on to receive OLT with reported 1 and 4-year 
overall survival retes of  96.2% and 92.1% respectively[51]. 
The promising results from these two groups suggest 
that this strategy may help identify patients with favorable 
tumor biology who would carry good prognosis for long-
term survival after OLT. Current recommendations call 
for an observation period of  at least 3-6 mo after down-
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staging with TACE before considering transplantation. 
The purpose of  this observation period is to assess the 
biological aggressiveness of  the tumor[21].
Pretreatment of patients on transplant list: Bridge to 
transplant
An ever-increasing demand for a relatively fixed pool 
of  deceased donor organs has caused HCC patients to 
spend more and more time on the wait list. This carries 
a high cumulative probability of  dropout due to intra-
hepatic or extrahepatic tumor progression. Llovet et al[52] 
and Yao et al[53] showed this probability to be between 
7%-11% at 6 mo and approximately 38% at 12 mo fol-
lowing enrollment for OLT. Consequently, several thera-
peutic procedures have been proposed as bridging treat-
ments for patients with HCC with the aims of  decreasing 
waiting list dropout rate, reducing HCC recurrence after 
transplantation and improving post-transplant overall 
survival[54]. The most commonly used bridging modali-
ties include TACE or TAE, ablation therapy with either 
RFA or percutaneous ethanol injection (PEI), and surgi-
cal resection. There are no randomized trials establishing 
efficacy of  these treatments and clinical practices vary 
greatly between transplant centers.
TACE/TAE: TACE/TAE has a well-established role 
as bridging therapy for patients awaiting OLT. The most 
commonly used TACE procedure involves an arterial 
infusion of  a lipiodol emulsion with a chemotherapeutic 
agent (e.g., doxorubicin, mitomycin or cisplatin) followed 
by embolization with gelfoam. Follow up cross sectional 
imaging is usually done 4-6 wk later to assess for com-
pleteness of  ablation (Figure 2). If  there is evidence of  
residual disease, TACE can be repeated[12,54]. 
Results from most series indicate complete tumor 
necrosis rates of  27%-57% in patients with stage Ⅰ and 
Ⅱ disease treated with TACE[50]. There is also evidence 
to suggest that the use of  TACE as neo-adjuvant therapy 
may provide survival benefit after transplantation as well. 
Yao et al[55] demonstrated a 5-year post transplant recur-
rence free survival of  93.8% for patients who received 
preoperative loco-regional therapy vs 80.6% in patients 
who were not pre-treated. Similarly, a report by Bharat 
et al[56] demonstrated a 5-year survival of  83.4% in pre-
treated patients vs 51.8% in patients who did not receive 
any preoperative loco-regional therapy. Interestingly, both 
of  these studies demonstrated treatment benefit only in 
patients with larger sized (T2-T4) tumors. Additionally, 
survival was highest in patients with 100% tumor necro-
sis in explant specimen irrespective of  size[56]. 
RFA: RFA is also being increasingly used as a bridge to 
transplantation in HCC patients in North America. Stud-
ies have reported complete tumor necrosis in 47%-75% 
of  patients on explant analysis. Predictably, the rate of  
tumor necrosis is highest in tumors less than 3 cm[54]. 
Mazzaferro et al[57] reported no patient drop-out due to 
disease progression after median waiting time of  9.5 mo 
Figure 2  Treatment of hepatocellular carcinoma with transarterial chemoembolization. A, B: Angiographic images demonstrate arterial blush of hepatocellular 
carcinoma (HCC) (white arrowhead) with a proper hepatic arterial injection. Coned down view shows tumor blush and stasis in the segmental arteries supplying the 
HCC following transarterial chemoembolization (B); C, D: Follow up magnetic resonance imaging 4 wk after treatment shows no residual arterial enhancement in the 
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in 50 patients undergoing pre-transplant RFA. The 1 and 
3-year post transplant survival was reported at 95% and 
83% respectively. 
Liver resection: The role of  liver resection as a bridge 
to transplantation is controversial. Approximately 70% 
of  patients develop recurrent disease after resection and 
about one-third of  them recur beyond Milan criteria 
making them transplant ineligible at most centers[33-35]. 
However, survival after salvage liver transplantation 
for patients with recurrences within Milan Criteria was 
shown in a recent meta-analysis to be comparable to sur-
vival after primary OLT[36]. Currently in the United States, 
patients on OLT waiting list who have already undergone 
liver resection for HCC are not awarded MELD score 
exception points, which makes it a less attractive option. 
Other modalities: PEI is one of  the oldest techniques 
for local treatment of  HCC and it is rarely used as a 
bridging treatment for transplantation[54]. Microwave 
ablation, high-intensity focused ultrasound (HIFU) 
ablation, percutaneous laser ablation, conformal radio 
therapy and transarterial radioembolization, are some of  
the new and upcoming techniques that may play a role as 
a bridge to transplantation in the future either alone or 
in combination therapy with other established modalities 
(Figure 3). A recent pilot study showed promising results 
with use of  HIFU ablation as bridging therapy for HCC 
patients on transplant wait list who were not candidates 
for TACE or radiofrequency ablation. Patients in the 
HIFU group had comparable percentages of  tumor ne-
crosis on explant specimen to TACE patients and this 
technique was found to be safe even in patients with 
advanced cirrhosis (Child-Pugh C). It still remains to be 
seen whether these promising initial results will be re-
produced in a RCT[58].
Non resectional ablative therapies
Ablative therapies have emerged in the past decade as ef-
fective treatment options for select patients with HCC. 
RFA and TACE/TAE are the more commonly employed 
ablative techniques and work by causing tumor necrosis. 
These techniques have shown to be reasonably effective 
for small tumors but also have significant limitations[15,57]. 
Consequently their role for primary treatment of  HCC 
is limited at the present time for patients with advanced 
disease that is not amenable for resection or transplanta-
tion or in patients who are at a prohibitively high risk for 
major surgery. Additionally, RFA and TACE/TAE are 
now increasingly being used as a bridge to transplantation 
in an attempt to decrease dropout rate for patients on 
transplant waiting list. Recent reports have also supported 
the use of  loco-regional ablative techniques to downstage 
patients with advanced HCC to ‘‘within Milan criteria’’ 
where they can be listed for OLT[21,50,51,56,59]. 
Microwave ablation, high intensity focused ultrasound 
Figure 3  Pretreatment of patients on transplant list (other modalities). A and B: Arterial enhancing hepatocellular carcinoma lesion in segment 5/8 (arrows) that 
shows subtle washout and possible pseudocapsule on delayed post-contrast imaging. This tumor was treated successfully using percutaneous microwave ablation; C: 
The tip of the microwave ablation probe positioned within the lesion (white dotted circle). Note the presence of a transjugular intrahepatic portosystemic shunt catheter 
(white dotted arrow) which helped direct placement of the probe on fluoroscopic images; D, E: Follow up magnetic resonance imaging 4 wk after ablation shows large 
ablation cavity covering the region of the previously seen tumor (arrows). There is no residual arterial enhancement suggesting complete tumor necrosis.
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and irreversible electroporation are some of  the newer 
ablative techniques that will likely find a place in the treat-
ment algorithm of  HCC alongside RFA and TACE. 
We will only discuss RFA under this section as others 
have been discussed under the section of  bridging for 
transplantation.
RFA: RFA has emerged as an effective treatment option 
for select patients with HCC limited to the liver and who 
do not meet criteria for resectability. RFA has also been 
increasingly used along with TACE/TAE as “bridging” 
therapy in patients awaiting liver transplantation or to 
downsize patients with stage Ⅲ/Ⅳ HCC to Milan cri-
teria for subsequent liver transplantation as discussed 
earlier. It is performed percutaneously in the majority of  
cases and effectiveness varies greatly with tumor size and 
location[21].
RFA involves application of  thermal energy to the 
lesion using high frequency alternating current. As the 
temperature of  the tumor tissue rises above 60 degrees 
Celsius, cells begin to die, resulting in an area of  coagu-
lative necrosis around the RF electrode. It can be used 
alone or in combination with TAE/TACE for manage-
ment of  HCC.
The HCC treatment algorithm established by the 
AASLD recommends ablative treatment for HCC nod-
ules with a maximal diameter of  3 cm in patients with 3 
or fewer tumors and in whom resection is otherwise con-
traindicated[60]. Chen et al[61] reported their results from 
a randomized control trial comparing survival between 
surgical resection and ablative therapy in 180 patients 
with solitary HCC up to 5 cm in size. They demonstrated 
comparable 1 and 4 year survival rates of  95.8%, 67.9% 
and 93.3%, 64.0% after ablative therapy and surgery 
respectively. The corresponding 1 and 4-year disease-
free survival rates were 85.9%, 46.4% and 86.6%, 51.6% 
respectively. Combination therapy with TACE and RFA 
been shown to be safe and effective for solitary HCC’s 
greater than 5 cm with approximate recurrence free sur-
vival times of  17 mo[59,62].
Choi et al[63] reported a 5 year local recurrence rate 
and corresponding survival rate of  11.9% and 51.6% 
respectively for 101 patients with recurrent HCC after 
hepatectomy, who then underwent percutaneous ultra-
sound guided RFA. In a recent prospective randomized 
trial, Peng et al[64] demonstrated that combination therapy 
with TACE and RFA was more effective than RFA alone 
for treatment of  recurrent HCC. This difference was 
significant for recurrent tumors greater than 3 cm in size. 
It is important to realize that although TACE and RFA 
may prolong survival, at this time they are not considered 
curative treatment options for HCC. Additionally like 
hepatic resection, ablative techniques do not address the 
risk of  HCC in the remnant cirrhotic liver. 
CONCLUSION
The surgical management of  HCC is complex and re-
quires an inter-disciplinary approach. Hepatic resection 
is the treatment of  choice for HCC in patients without 
cirrhosis and is indicated in some patients with early 
cirrhosis (Child-Pugh A). Effectiveness of  surgery is 
dependent on ability to achieve negative margins while 
maintaining an adequately functioning liver remnant. 
Large HCC, multifocal disease, underlying cirrhosis and 
vascular invasion by the tumor are some of  the major 
factors negatively impacting outcome after surgical resec-
tion. Liver transplantation is the established standard of  
care for patients with cirrhosis and HCC meeting Milan 
criteria and in select patients with HCC beyond Milan 
but within UCSF criteria. Neo-adjuvant loco-regional 
therapy (TACE/TAE, RFA etc.) followed by a period 
of  observation must be considered for patients beyond 
Milan criteria in an attempt do downstage them to meet 
Milan criteria. Loco-regional therapies (TACE/TAE and 
RFA) can also be used as a bridge to transplantation with 
favorable oncologic outcomes and reduced dropout rates 
in patients awaiting OLT. The role of  hepatic resection as 
bridge for transplantation is controversial.
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